A 39-year-old Hispanic female presented to our breast clinic with a 2.5-year history of a right breast lump that had been gradually increasing in size. The patient did not have associated breast pain, skin changes, nipple discharge, or a history of breast trauma. Her past medical history was significant only for hypercholesterolemia. Her menarche was at age 13, and she was gravida 2 para 1, with one miscarriage. She was 20 years old at the time of her first birth. There was no family history of breast or ovarian cancer.
. 39-year-old female with lymphoepithelioma-like carcinoma of the right breast. Right mediolateral-oblique (A), craniocaudal (B), and spot magnification craniocaudal (C) digital mammographic projections demonstrate a 2.7-cm, irregularshaped, high-density mass with microlobulated margins located at the 1 o'clock position at mid depth. Metallic BB markers overlie the nipple and the palpable mass on the mediolateral-oblique and craniocaudal projections.
Fig. 2 (left)
. 39-year-old female with lymphoepithelioma-like carcinoma of the right breast. Ultrasound images in transverse (A) and longitudinal (B) orientations show a 2.7 x 2.5 x 2.5-cm, nonparallel, irregular-shaped, hypoechoic mass with heterogeneous internal echogenicity, microlobulated margins, and posterior acoustic enhancement. The mass is located at the 1 o'clock position and corresponds to the mammographic mass. Fig. 3 (right) . 39-year-old female with lymphoepithelioma-like carcinoma of the right breast. Contrast-enhanced computed tomography axial (A), coronal reformatted (B), and sagittal reformatted (C) images demonstrate an irregular-shaped, soft-tissue-density mass with heterogeneous internal enhancement in the right breast upper inner quadrant.
could be seen on a subsequent ultrasound examination, indicating an excellent treatment response (Fig. 4) . Surgical therapy consisted of a needle-localized wide local excision and a sentinel lymph-node biopsy.
The right breast wide local excision specimen showed one small nodular focus of residual tumor measuring 4 mm. Microscopic examination revealed poorly defined nests and cords of undifferentiated epithelial cells with a prominent lymphoplasmacytic infiltrate (Figs. 5A, B) . Immunohistochemical staining of the neoplastic cells demonstrated positivity for epithelial markers CAM 5.2 ( Fig. 5C) , HMW, and CK7. These cells were negative for EpsteinBarr virus Latent Membrane Protein. The lymphocytes were predominantly CD3-positive ( the breast.
Five out of five sentinel lymph nodes removed were negative for tumor involvement. Final staging was ypT1aN0M0, Stage IA. Postoperative adjuvant radiation therapy was administered. Given the ER-positive tumor and premenopausal status of the patient, antihormonal therapy with tamoxifen was also initiated. To date, there is no evidence of local or distant recurrence after 2 years of followup.
Discussion
Lymphoepithelioma-like carcinoma (LELC) is a malignancy that microscopically resembles nasopharyngeal lymphoepithelioma. While LELC can occur in many organ systems, this entity rarely occurs in the breast. Kumar and Kumar (1) published the first instance of LELC of the breast in 1994, and since then fewer than 20 cases of this tumor have been documented in the literature (2-13). The age of initial presentation of the previous cases ranged from 37 to 69 years (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . At this time, the etiology of LELC of the breast remains unknown. LELC tumor cells in other organ systems have been associated with varying degrees of Epstein-Barr virus (EBV) genome expression; however, there have been no documented cases of EBV detected in LELC of the breast (2). The clinical and imaging findings of LELC of the breast are similar to that of other primary breast malignancies. Clinically, LELC of the breast often presents as a palpable breast mass. The mammogram may show a high-density, irregular-shaped mass with microlobulated margins, a circumscribed mass, or a poorly defined mass that can appear mammographically as a focal asymmetry (3, 4) . Sonographic evaluation may demonstrate a solid hypoechoic mass with microlobulated margins and posterior acoustic enhancement, or an area of subtle abnormal parenchyma (4, 5) . Computed tomography may reveal a heterogeneously enhancing or low-density mass (6) . Previously documented tumor sizes ranged from 1 cm to 4 cm at the time of diagnosis. Four prior cases have noted metastatic lymphnode involvement; therefore, thorough examination of the axillary and supraclavicular regions is important to identify potential lymphadenopathy (6) .
The differential diagnosis of LELC of the breast based on clinical and imaging findings includes primary invasive breast cancers, metastasis, and lymphoma (Table 1) . Once tissue has been obtained, the differential diagnoses are usually narrowed to lymphoma and medullary carcinoma. Histologically, LELC of the breast can appear similar to lymphoma due to the presence of undifferentiated cancer cells surrounded by a prominent lymphocytic infiltrate. Medullary carcinoma is also a consideration, because LELC of the breast shares a similar cellular morphology. Application of immunohistochemistry and careful investigation of the tissue architecture are helpful in distinguishing these entities (6) .
Since LELC of the breast is so rare, limited information is available to direct optimal oncologic management. All reported instances in the literature have been treated surgically, either with wide local excision or mastectomy, and with or without adjuvant radiotherapy. Chemotherapy had been used in three previous cases; however, only one therapeutic regimen has been described in the literature (cyclophosphamide, epirubicin, and 5-fluorouracil), and this was administered only after the patient presented with chestwall recurrence (5, 7, 8) . This patient later developed lung metastasis (7) . One patient was found to have developed LELC of the contralateral breast three years after the initial diagnosis. The remaining cases demonstrated no evidence of disease at the time of followup (range: 3-72 months).
To our knowledge, there has been no documented use of neoadjuvant chemotherapy prior to surgical treatment of LELC of the breast. Our case demonstrated excellent treatment response to a neoadjuvant chemotherapy regimen of docetaxel, doxorubicin, and cyclophosphamide prior to breast-conserving surgical excision. Given the paucity of previous cases to guide physicians encountering this entity, our experience may help facilitate future management decisions.
